Tìm theo
Pemetrexed
Các tên gọi khác (2) :
  • Pemetrexed
  • SID50112739
Thuốc Gốc
Small Molecule
CAS: 150399-23-8
ATC: L01BA04
ĐG : Eli Lilly & Co. , http://www.lilly.com
CTHH: C20H21N5O6
PTK: 427.4106
Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C20H21N5O6
Phân tử khối
427.4106
Monoisotopic mass
427.149183429
InChI
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m1/s1
InChI Key
InChIKey=WBXPDJSOTKVWSJ-CYBMUJFWSA-N
IUPAC Name
(2R)-2-{[4-(2-{2-amino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
Traditional IUPAC Name
pemetrexed
SMILES
NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@H](CCC(O)=O)C(O)=O)N1
Độ hòa tan
4.55e-02 g/l
logP
-1.5
logS
-4
pKa (strongest acidic)
3.34
pKa (Strongest Basic)
0.96
PSA
186.97 Å2
Refractivity
109.45 m3·mol-1
Polarizability
43.04 Å3
Rotatable Bond Count
9
H Bond Acceptor Count
9
H Bond Donor Count
6
Physiological Charge
-2
Number of Rings
3
Bioavailability
1
Ghose Filter
true
MDDR-Like Rule
true
Dược Lực Học : Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.
Cơ Chế Tác Dụng : Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer. Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.
Dược Động Học :

▧ Volume of Distribution :
* 16.1 L
▧ Protein binding :
81%
▧ Metabolism :
Metabolized by Cytochrome P450 Enzymes
▧ Route of Elimination :
Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.
▧ Half Life :
3.5 hours
▧ Clearance :
* 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]
Chỉ Định : Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Tương Tác Thuốc :
  • Ketoprofen The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy.
  • Sulindac The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy.
  • Tiaprofenic acid Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered.
  • Tolmetin Tolmetin may decrease the renal excretion of Pemetrexed in patients with decreased creatinine clearance. Tolmetin may be withheld in these patients from 2 days before to 2 days after Pemetrexed administration.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Alimta 100 mg vial
    Giá bán buôn : USD >606.72
    Đơn vị tính : vial
  • Biệt dược thương mại : Alimta 500 mg vial
    Giá bán buôn : USD >3033.6
    Đơn vị tính : vial
  • Biệt dược thương mại : Alimta 500 mg Solution Vial
    Giá bán buôn : USD >3154.94
    Đơn vị tính : vial
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Alimta
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00642
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=60843
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505640
ChemSpider
http://www.chemspider.com/Chemical-Structure.54830.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0002-7640-01
PharmGKB
http://www.pharmgkb.org/drug/PA10810
Wikipedia
http://en.wikipedia.org/wiki/Pemetrexed
RxList
http://www.rxlist.com/cgi/generic3/alimta.htm
Drugs.com
http://www.drugs.com/cdi/pemetrexed.html
... loading
... loading